OBJECTIVE： To evaluate the economics of Yindan xintai dropping pills in the treatment of angina pectoris caused by coronary heart disease from societal perspectives. METHODS： Therapy regimens related to Yindan xintai dropping pills and control regimens were selected from published literatures included in database， and the cost of therapy regimens and clinical effect data were extracted from literatures. Contingent evaluation method was used to measure people’s willingness-to-pay for angina pectoris treatments. An econometric model was conducted to transfer the effectiveness data to benefit data. The economics of treatment was evaluated depending upon net benefit or incremental net benefit indicator. RESULTS & CONCLUSIONS： When Yindan xintai dropping pills is used alone， its net benefit is ＞0， indicating economical advantage； 56 d therapy regimen is better than 28 d therapy. When Yindan xintai dropping pills were combined with glyceryl trinitrate tablet， Isosorbide mononitrate sustained-release tablet， Simvastatin dispersible tablet and other drugs， its incremental net benefit is better than control regimens and has good economics.